# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 21, "Diabetes Obes Metab .", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasJournal> \"Diabetes Obes Metab .\"."
1, PublicationYear, 22, 26, "2017", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasPublicationYear> \"2017\"."
55, Title, 107, 336, "Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre ,", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasTitle> \"Efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea : a 24 - week , multicentre ,\"."
97778, Gemigliptin, 130, 141, "gemigliptin", "", 
176, Precondition, 186, 306, "patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea", "", 
3, Type2Diabetes, 200, 224, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
4, Metformin, 279, 288, "metformin", "", 
5, Sulfonylureas, 293, 306, "sulphonylurea", "", 
6, Duration, 311, 320, "24 - week", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasCTduration> \"24 - week\"."
7, Multicenter, 323, 334, "multicentre", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
8, Randomized, 337, 347, "randomized", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
55, Title, 337, 412, "randomized , double - blind , placebo - controlled study ( TROICA study ) .", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasTitle> \"randomized , double - blind , placebo - controlled study ( TROICA study ) .\"."
9, DoubleBlind, 350, 364, "double - blind", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
10, Placebo, 367, 374, "placebo", "", 
11, Author, 413, 419, "Ahn CH", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Ahn CH\"."
12, Author, 428, 434, "Han KA", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Han KA\"."
13, Author, 443, 448, "Yu JM", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Yu JM\"."
14, Author, 457, 463, "Nam JY", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Nam JY\"."
15, Author, 472, 478, "Ahn KJ", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Ahn KJ\"."
16, Author, 487, 492, "Oh TK", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Oh TK\"."
17, Author, 501, 507, "Lee HW", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Lee HW\"."
18, Author, 516, 522, "Lee DH", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Lee DH\"."
19, Author, 531, 536, "Kim J", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Kim J\"."
20, Author, 545, 553, "Chung CH", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Chung CH\"."
21, Author, 563, 570, "Park TS", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Park TS\"."
22, Author, 580, 586, "Kim BJ", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Kim BJ\"."
23, Author, 596, 603, "Park SW", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Park SW\"."
24, Author, 613, 620, "Park HK", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Park HK\"."
25, Author, 630, 636, "Lee KJ", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Lee KJ\"."
26, Author, 646, 652, "Kim SW", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Kim SW\"."
27, Author, 662, 669, "Park JH", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Park JH\"."
28, Author, 679, 684, "Ko KP", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Ko KP\"."
29, Author, 694, 700, "Kim CH", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Kim CH\"."
30, Author, 710, 715, "Lee H", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Lee H\"."
31, Author, 725, 732, "Jang HC", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Jang HC\"."
32, Author, 749, 756, "Park KS", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasAuthor> \"Park KS\"."
33, SouthKorea, 885, 890, "Korea", "", "<http://ctro/data#Population_77933> <http://ctro/data#hasCountry> <http://ctro/data#SouthKorea>."
34, SouthKorea, 966, 971, "Korea", "", 
35, SouthKorea, 1072, 1077, "Korea", "", 
36, SouthKorea, 1180, 1185, "Korea", "", 
37, SouthKorea, 1291, 1296, "Korea", "", 
38, SouthKorea, 1390, 1395, "Korea", "", 
39, SouthKorea, 1483, 1488, "Korea", "", 
40, SouthKorea, 1593, 1598, "Korea", "", 
41, SouthKorea, 1683, 1688, "Korea", "", 
42, SouthKorea, 1795, 1800, "Korea", "", 
42, SouthKorea, 1892, 1897, "Korea", "", 
43, SouthKorea, 1990, 1995, "Korea", "", 
44, SouthKorea, 2079, 2084, "Korea", "", 
45, SouthKorea, 2172, 2177, "Korea", "", 
46, SouthKorea, 2256, 2261, "Korea", "", 
47, SouthKorea, 2356, 2361, "Korea", "", 
48, SouthKorea, 2451, 2456, "Korea", "", 
49, SouthKorea, 2543, 2548, "Korea", "", 
50, SouthKorea, 2628, 2633, "Korea", "", 
51, SouthKorea, 2670, 2675, "Korea", "", 
52, SouthKorea, 2775, 2780, "Korea", "", 
53, SouthKorea, 2880, 2885, "Korea", "", 
54, SouthKorea, 3053, 3058, "Korea", "", 
62, ObjectiveDescription, 3068, 3238, "To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) .", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasObjectiveDescription> \"To assess the efficacy and safety of gemigliptin , a dipeptidyl peptidase - 4 inhibitor , added to metformin and sulphonylurea in patients with type 2 diabetes ( T2DM ) .\"."
97779, Gemigliptin, 3105, 3116, "gemigliptin", "", 
58, Metformin, 3167, 3176, "metformin", "", 
59, Sulfonylureas, 3181, 3194, "sulphonylurea", "", 
60, Type2Diabetes, 3212, 3227, "type 2 diabetes", "", 
61, Type2Diabetes, 3230, 3234, "T2DM", "", 
63, Randomized, 3278, 3288, "randomized", "", 
64, DoubleBlind, 3291, 3305, "double - blind", "", 
65, Placebo, 3308, 3315, "placebo", "", 
66, NumberPatientsCT, 3338, 3341, "219", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasNumberPatientsCT> \"219\"."
67, Ethnicity, 3342, 3348, "Korean", "", "<http://ctro/data#Ethnicity_77935> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_77933> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_77935>."
244, Precondition, 3342, 3412, "Korean patients inadequately controlled with metformin and glimepiride", "", "<http://ctro/data#Population_77933> <http://ctro/data#hasPrecondition> \"Korean patients inadequately controlled with metformin and glimepiride\"."
68, Metformin, 3387, 3396, "metformin", "", 
69, Glimepiride, 3401, 3412, "glimepiride", "", 
71, Randomized, 3433, 3443, "randomized", "", 
97780, Gemigliptin, 3447, 3458, "gemigliptin", "", "<http://ctro/data#Medication_79129> <http://ctro/data#hasDrug> <http://ctro/data#Gemigliptin>."
246, DoseValue, 3459, 3461, "50", "", "<http://ctro/data#Medication_79129> <http://ctro/data#hasDoseValue> \"50\"."
74, mg, 3464, 3466, "mg", "", "<http://ctro/data#Medication_79129> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
75, Frequency, 3467, 3477, "once daily", "", "<http://ctro/data#Intervention_79136> <http://ctro/data#hasFrequency> \"once daily\"."
76, Placebo, 3481, 3488, "placebo", "", "<http://ctro/data#Medication_79142> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
77, Metformin, 3498, 3507, "metformin", "", "<http://ctro/data#Medication_79149> <http://ctro/data#hasDrug> <http://ctro/data#Metformin>."
78, Glimepiride, 3512, 3523, "glimepiride", "", "<http://ctro/data#Medication_79156> <http://ctro/data#hasDrug> <http://ctro/data#Glimepiride>."
79, HbA1c, 3561, 3581, "glycated haemoglobin", "", 
80, HbA1c, 3584, 3589, "HbA1c", "", 
81, TimePoint, 3603, 3611, "baseline", "", 
82, TimePoint, 3615, 3622, "week 24", "", 
83, TimePoint, 3639, 3647, "baseline", "", 
84, HbA1c, 3648, 3653, "HbA1c", "", "<http://ctro/data#Endpoint_77942> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
85, BaseLineValue, 3658, 3663, "8 . 2", "", "<http://ctro/data#Outcome_79199> <http://ctro/data#hasBaselineValue> \"8 . 2\". <http://ctro/data#Outcome_79226> <http://ctro/data#hasBaselineValue> \"8 . 2\"."
86, Percentage, 3664, 3665, "%", "", "<http://ctro/data#Endpoint_77942> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
97781, Gemigliptin, 3699, 3710, "gemigliptin", "", 
88, Metformin, 3714, 3723, "metformin", "", 
89, Glimepiride, 3728, 3739, "glimepiride", "", 
252, HbA1c, 3762, 3767, "HbA1c", "", 
91, TimePoint, 3778, 3785, "week 24", "", "<http://ctro/data#Outcome_79199> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_79226> <http://ctro/data#hasTimePoint> \"week 24\"."
92, Placebo, 3800, 3807, "placebo", "", 
93, Mean, 3849, 3853, "mean", "", "<http://ctro/data#Mean_77944> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_77942> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_77944>."
150, DiffGroupAbsValue, 3861, 3869, "- 0 . 87", "", "<http://ctro/data#DiffBetweenGroups_79253> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 87\"."
94, Percentage, 3870, 3871, "%", "", 
98, ConfIntervalDiff, 3874, 3930, "95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 %", "", "<http://ctro/data#DiffBetweenGroups_79253> <http://ctro/data#hasConfIntervalDiff> \"95 % confidence interval [ CI ] - 1 . 09 % to - 0 . 64 %\"."
96, Percentage, 3915, 3916, "%", "", 
97, Percentage, 3929, 3930, "%", "", 
264, FastingPlasmaGlucose, 3935, 3957, "Fasting plasma glucose", "", "<http://ctro/data#Endpoint_77947> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
97782, Gemigliptin, 4000, 4011, "gemigliptin", "", 
265, Reduction, 4016, 4022, "0 . 93", "", "<http://ctro/data#Outcome_79316> <http://ctro/data#hasChangeValue> \"0 . 93\"."
102, Millimoles_per_litre, 4025, 4033, "mmol / L", "", "<http://ctro/data#Endpoint_77947> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
104, ConfIntervalChangeValue, 4036, 4075, "95 % CI - 1 . 50 to - 0 . 35   mmol / L", "", "<http://ctro/data#Outcome_79316> <http://ctro/data#hasConfIntervalChangeValue> \"95 % CI - 1 . 50 to - 0 . 35   mmol / L\"."
103, Millimoles_per_litre, 4067, 4075, "mmol / L", "", 
111, HbA1c_target, 4132, 4152, "HbA1c level of < 7 %", "", "<http://ctro/data#Endpoint_77952> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
106, Percentage, 4151, 4152, "%", "", 
112, PercentageAffected, 4155, 4161, "39 . 3", "", "<http://ctro/data#Outcome_79262> <http://ctro/data#hasPercentageAffected> \"39 . 3\"."
113, PercentageAffected, 4167, 4172, "5 . 5", "", "<http://ctro/data#Outcome_79289> <http://ctro/data#hasPercentageAffected> \"5 . 5\"."
114, PvalueDiff, 4177, 4186, "P < . 001", "", "<http://ctro/data#DiffBetweenGroups_79370> <http://ctro/data#hasPvalueDiff> \"P < . 001\"."
97783, Gemigliptin, 4196, 4207, "gemigliptin", "", 
110, Placebo, 4226, 4233, "placebo", "", 
117, EndPointDescription, 4242, 4259, "Total cholesterol", "", "<http://ctro/data#EndPointDescription_77958> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_77957> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_77958>."
277, ObservedResult, 4242, 4376, "Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group", "", "<http://ctro/data#Outcome_79379> <http://ctro/data#hasObservedResult> \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\". <http://ctro/data#Outcome_79406> <http://ctro/data#hasObservedResult> \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\". <http://ctro/data#Outcome_79469> <http://ctro/data#hasObservedResult> \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\". <http://ctro/data#Outcome_79496> <http://ctro/data#hasObservedResult> \"Total cholesterol and LDL cholesterol were modestly but significantly reduced in the gemigliptin group compared with the placebo group\"."
118, EndPointDescription, 4264, 4279, "LDL cholesterol", "", "<http://ctro/data#EndPointDescription_77963> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_77962> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_77963>."
97784, Gemigliptin, 4327, 4338, "gemigliptin", "", 
116, Placebo, 4363, 4370, "placebo", "", 
278, DiffGroupAbsValue, 4379, 4387, "- 0 . 21", "", "<http://ctro/data#DiffBetweenGroups_79433> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 21\"."
123, Millimoles_per_litre, 4390, 4398, "mmol / L", "", "<http://ctro/data#Endpoint_77957> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>. <http://ctro/data#Endpoint_77962> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
284, ConfIntervalDiff, 4401, 4440, "95 % CI - 0 . 38 to - 0 . 03   mmol / L", "", "<http://ctro/data#DiffBetweenGroups_79433> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 38 to - 0 . 03   mmol / L\"."
124, Millimoles_per_litre, 4432, 4440, "mmol / L", "", 
119, EndPointDescription, 4445, 4462, "total cholesterol", "", 
279, DiffGroupAbsValue, 4465, 4473, "- 0 . 18", "", "<http://ctro/data#DiffBetweenGroups_79523> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 18\"."
125, Millimoles_per_litre, 4476, 4484, "mmol / L", "", 
285, ConfIntervalDiff, 4487, 4526, "95 % CI - 0 . 34 to - 0 . 01   mmol / L", "", "<http://ctro/data#DiffBetweenGroups_79523> <http://ctro/data#hasConfIntervalDiff> \"95 % CI - 0 . 34 to - 0 . 01   mmol / L\"."
126, Millimoles_per_litre, 4518, 4526, "mmol / L", "", 
120, EndPointDescription, 4531, 4546, "LDL cholesterol", "", 
131, Hypoglycemia, 4568, 4581, "hypoglycaemia", "", "<http://ctro/data#Endpoint_77967> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
134, PercentageAffected, 4586, 4591, "9 . 4", "", "<http://ctro/data#Outcome_79532> <http://ctro/data#hasPercentageAffected> \"9 . 4\"."
97787, Gemigliptin, 4601, 4612, "gemigliptin", "", 
135, PercentageAffected, 4623, 4628, "2 . 7", "", "<http://ctro/data#Outcome_79559> <http://ctro/data#hasPercentageAffected> \"2 . 7\"."
133, Placebo, 4638, 4645, "placebo", "", 
147, ConclusionComment, 4668, 4801, "Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea .", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasConclusionComment> \"Gemigliptin significantly improved glycaemic control in patients with T2DM inadequately controlled with metformin and sulphonylurea .\"."
97785, Gemigliptin, 4668, 4679, "Gemigliptin", "", 
139, Type2Diabetes, 4738, 4742, "T2DM", "", 
140, Metformin, 4772, 4781, "metformin", "", 
141, Sulfonylureas, 4786, 4799, "sulphonylurea", "", 
148, ConclusionComment, 4802, 4959, "The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea .", "", "<http://ctro/data#ClinicalTrial_77914> <http://ctro/data#hasConclusionComment> \"The incidence of hypoglycaemia was higher with gemigliptin than with placebo , which highlights the importance of optimal dose adjustment for sulphonylurea .\"."
143, Hypoglycemia, 4819, 4832, "hypoglycaemia", "", 
97786, Gemigliptin, 4849, 4860, "gemigliptin", "", 
145, Placebo, 4871, 4878, "placebo", "", 
146, Sulfonylureas, 4944, 4957, "sulphonylurea", "", 
149, PMID, 5028, 5036, "28026912", "", "<http://ctro/data#Publication_77886> <http://ctro/data#hasPMID> \"28026912\"."
